Skip to main content

Table 2 Primary and secondary endpoints

From: Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

 

Endpoint details

Primary endpoint

Change in of NT-proBNP level from baseline to 6 months after randomization

Secondary endpoints

The frequency of NT-proBNP increment > 10% from baseline

Composite of all-cause mortality and readmission

All-cause mortality rate and readmission rate

Change in systolic/diastolic blood pressure at sitting position, control/response rate of blood pressure

Quality of life assessment by the MLHFQ, Visual Analog Scale

Drug compliance

  1. MLHFQ Minnesota Living with Heart Failure Questionnaire, NT-proBNP N-terminal pro B-type natriuretic peptide